Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Hepatitis B · Mixed Dyslipidemia · ARWR

Arrowhead Pharmaceuticals Ireland

Arrowhead Pharmaceuticals Ireland Limited

Arrowhead Pharmaceuticals Ireland patent portfolio — 126 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US HQ
746 Employees
Public company Type
ARWR · NYSE Ticker
Company details
Status
Public
HQ
177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US
Employees
746
Programs
63
Drugs
34
Patents
126
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Arrowhead Pharmaceuticals Ireland patents

126 pharmaceutical patents indexed for Arrowhead Pharmaceuticals Ireland. 0 expire within 24 months.

Arrowhead Pharmaceuticals Ireland has 126 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

126 patents

Patent portfolio

Page 3 of 3

  1. US 9173896

    RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9150862

    siRNA targeting VEGFA and methods for treatment in vivo

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9139834

    RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9139833

    Modified small interfering RNA molecules and methods of use

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9133462

    dsRNA for treating viral infection

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9114152

    Transferrin/transferrin receptor-mediated siRNA delivery

    Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9107957

    Peptide-based in vivo siRNA delivery system

    Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9096637

    Organic compositions to treat HSF1-related diseases

    Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9089611

    Poly(vinyl ester) polymers for in vivo nucleic acid delivery

    Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9084808

    Modified small interfering RNA molecules and methods of use

    Expires Mon Jul 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9080175

    Organic compositions to treat Beta-ENaC-related diseases

    Expires Mon Jul 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9074212

    RNAi inhibition of alpha-ENaC expression

    Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9011919

    Compositions for targeted delivery of siRNA

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8946176

    Compositions and methods for inhibiting expression of RRM2 genes

    Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8932572

    Poly(vinyl ester) polymers for in vivo nucleic acid delivery

    Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8933047

    Poly(acrylate) polymers for in vivo nucleic acid delivery

    Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8809293

    Compositions and methods for inhibiting gene expression of hepatitis B virus

    Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8802773

    In vivo polynucleotide delivery conjugates having enzyme sensitive linkages

    Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8765817

    Selective inhibitors of EG5 motors and methods of use

    Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8715529

    Synthesis and applications of triazaborolopyridinium compounds and substituted triazaborolopyridinium compounds and methods of use

    Expires Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8658211

    Polyconjugates for in vivo delivery of polynucleotides

    Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8541548

    Compounds and methods for reversible modification of biologically active molecules

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8501930

    Peptide-based in vivo siRNA delivery system

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8426554

    In vivo polynucleotide delivery conjugates having enzyme sensitive linkages

    Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8349899

    Selective inhibitors of EG5 motors and methods of use

    Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8313772

    Compositions for targeted delivery of siRNA

    Expires Mon Nov 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8217015

    Endosomolytic polymers

    Expires Mon Jul 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8211468

    Endosomolytic polymers

    Expires Mon Jun 28 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8138383

    Membrane active heteropolymers

    Expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8137695

    Polyconjugates for in vivo delivery of polynucleotides

    Expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Arrowhead Pharmaceuticals Ireland have?

126 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Arrowhead Pharmaceuticals Ireland patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.